Since the current nomenclature of psychiatric medication is confused and confusing, both to the patient and the care giver, the NbN was initiated to update the way medications is being named.
Our Rationale and Guidelines
Up till now, medicines were being named according to arbitrary descriptors based on indication, (antidepressants, antipsychotics, etc.) or chemical structure. It is our belief that a change was necessary and that the name should be chosen with reference to contemporary pharmacological knowledge, and on the medication’s mode of action.
NbN’s Scientific Reliability and Bias-Free Approach
Five major international neuropsychopharmacological research organizations joined forces to bring you this new and improved nomenclature. The NbN is a joint initiative of ECNP, ACNP, CINP, AsCNP and IUPHARM, and is fully supported by the ECNP.
All expenses related to the development of the nomenclature were covered by ECNP, as part of its ongoing mission to encourage advances in the understanding of the brain’s function, which are translated into better treatments and improved public health.
Throughout the process, NbN received no direct or indirect support from any pharmacological company or other organization, which means that our main agenda was and is to provide an improved method of naming and relating to different psychiatric medications for the benefit of both patient and care giver.
Updates and Feedback
Taking into account new findings and insights, including feedback that reflects the physicians’ clinical experience, the taskforce will update the NbN twice a year (May and September).
NbN’s app also allows and encourages you to submit your feedback and suggestions.